Rapamycin

Rapamycin（Aladdin S115842≥98%, S293790 ≥95%, R1371984-GMP, R408790 10mM in DMSO ） is an immunosuppressive agent widely used to prevent transplant rejection in organ recipients. Its primary mechanism of action involves inhibition of mTOR signaling through complex formation with FK-binding protein 12 (FKBP12), which prevents mTOR activation. As a result, IL-2–mediated signal transduction is blocked, thereby suppressing B-cell and T-cell activation.

Beyond its immunosuppressive effects, rapamycin demonstrates significant antiproliferative activity in cancer research models. In osteosarcoma cells, rapamycin induces G1-phase cell cycle arrest and autophagy, resulting in reduced proliferation; corresponding animal xenograft models confirmed decreased tumor growth. Similarly, in breast cancer cells, rapamycin promotes G1 arrest, autophagy, and apoptosis.

Combination therapy has also shown promise: when used with Vismodegib (GDC-0449, Aladdin V127477 ≥98%, V408303 10mM in DMSO), rapamycin enhanced anticancer efficacy in both cell and animal models of biliary tract cancer, reducing cell viability, proliferation, and tumor growth. Clinically, rapamycin has been reported to reduce visceral tumor volume in patients with tuberous sclerosis complex–associated skin tumors.

Recent findings highlight rapamycin’s potential in aging and age-related disorders. In yeast, rapamycin administration increased chronological life span, likely due to enhanced accumulation of storage carbohydrates and improved stress resistance resulting from mTOR inhibition. In genetically diverse murine models, treatment extended both median and maximal life span, even when administered late in life.

Because mTOR signaling is strongly linked to oxidative stress, rapamycin’s ability to attenuate this pathway is considered a key contributor to its protective effects against age-related pathologies. By mitigating oxidative damage, rapamycin appears to not only slow disease progression but also promote overall longevity.

References:

1. Yang H, Rudge DG, Koos JD, et al. Nature. 2013 May 9;497(7448):217-23.

2. Zhao S, Lu N, Chai Y, et al. J BUON. 2015 Mar-Apr;20(2):588-94.

3. Tengku Din TA, Seeni A, Khairi WN, et al. Asian Pac J Cancer Prev. 2014;15(24):10659-63.

4. Zuo M, Rashid A, Churi C, et al. Br J Cancer. 2015 Mar 17;112(6):1042-51.

5. Nathan N, Wang JA, Li S, et al. J Am Acad Dermatol. 2015 Nov;73(5):802-8.

6. Powers RW 3rd, Kaeberlein M, Caldwell SD, et al. Genes Dev. 2006 Jan 15;20(2):174-84.

7. Harrison DE, Strong R, Sharp ZD, et al. Nature. 2009 Jul 16;460(7253):392-5.

8. Perl A. Ann N Y Acad Sci. 2015 Jun;1346(1):33-44. 

Aladdin: https://www.aladdinsci.com/